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The tumor suppressor protein p53 is activated by distinct cel-
lular stresses including radiation, hypoxia, type I interferon, and
DNA/RNA virus infection. The transactivation domain of p53
contains a phosphorylation site at Ser20 whosemodification sta-
bilizes the binding of the transcriptional co-activator p300 and
whose mutation in murine transgenics induces B-cell lym-
phoma. Although the checkpoint kinase CHK2 is implicated in
promoting Ser20 site phosphorylation after irradiation, the
enzyme that triggers this phosphorylation afterDNAviral infec-
tion is undefined. Using human herpesvirus 6B (HHV-6B) as a
virus that induces Ser20 site phosphorylation of p53 in T-cells,
we sought to identify the kinase responsible for this virus-in-
duced p53 modification. The p53 Ser20 kinase was fractionated
and purified using cation, anion, and dye-ligand exchange chro-
matography. Mass spectrometry identified casein kinase 1
(CK1) and vaccinia-related kinase 1 (VRK1) as enzymes that co-
eluted with virus-induced Ser20 site kinase activity. Immu-
nodepletion of CK1 but not VRK1 removed the kinase activity
from the peak fraction, and bacterially expressed CK1 exhibited
Ser20 site kinase activity equivalent to that of the virus-induced
native CK1. CK1modified p53 in a docking-dependentmanner,
which is similar to other knownSer20 site p53kinases. Low levels
of the CK1 inhibitor D4476 selectively inhibited HHV-6B-in-
duced Ser20 site phosphorylation of p53. However, x-ray-in-
duced Ser20 site phosphorylation of p53 was not blocked by
D4476. These data highlight a central role for CK1 as the Ser20
site kinase for p53 in DNA virus-infected cells but also suggest
that distinct stresses may selectively trigger different protein
kinases to modify the transactivation domain of p53 at Ser20.
The tumor suppressor protein p53 is a key player in the sur-
vival or death decision that cells face after exposure to a variety
of metabolic and genotoxic stresses (1). The transient accumu-
lation and activation of p53 in response to various cellular
stresses enables the protein to modulate the expression of
numerous genes involved in cell cycle arrest, DNA repair,
and/or apoptosis. The initiation of either transient cell cycle
arrest and damage repair or apoptosis is dependent on the cell
and damage type, the severity of damage, and the cellular
microenvironment. Phosphorylation and acetylation events
that control interactions between the transcription factor p53
and its negative regulators (Mdm2, COP1, and Pirh2) or co-
activators (p300) are ultimately involved inmodulating p53-de-
pendent gene expression in response to cellular stress (2). In
particular, phosphorylation at Thr18 within the N-terminal
conserved BOX-I domain of p53 blocks the binding of Mdm2,
whereas phosphorylation at Ser20, also within the BOX-I
domain, enables the binding of p300 (3–5). Thus, phosphoryl-
ation in this transactivation domain serves to stimulate rather
than inhibit p53 function. In addition, phosphorylation at
Ser392 within the C terminus of p53 stimulates the sequence-
specific DNA-binding function of p53 (6).
The generation of transgenic mice with phosphoacceptor
site mutations (to alanine) at the key regulatory phosphoaccep-
tor sites of Ser20 and Ser392 equivalents inmurine p53 results in
elevated cancer incidence. Mutation of Ser20 results in
enhanced spontaneous B-cell lymphoma and attenuated dam-
age-induced apoptosis in B-cells (7), whereas mutation of
Ser392 results in enhanced UV-induced skin cancer or carcin-
ogen-induced bladder cancer (8, 9). These biochemical and
genetic results highlight the critical role that phosphoryla-
tion of p53 can play in modulating its tumor suppressor
function and the likelihood that these phosphorylation
events are “stress-” and/or cell type-specific. Presumably,
the use of transgenic phosphomutated systems will further
uncover the cell- and stress-specific function of these multi-
ple covalent modifications.
Although members of the calcium calmodulin kinase super-
family, particularly the checkpoint kinases 1 and 2 (CHK1 and
CHK2) and death-associated protein kinase 1 (DAPK-1), are
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genetic activators of the p53 pathway, other kinases have also
been shown to phosphorylate and activate p53. For example,
vaccinia-related kinase 1 (VRK1) and casein kinase 1 (CK1)
have been reported to phosphorylate p53 at Thr18 (10),
although the latter requires prior phosphorylation of p53 at
Ser15 (11). Controversy remains as to which kinases are most
important for the activation of p53 in response to distinct cel-
lular stress. It is possible that the exact kinase(s) involved and
the residue(s) modified are specific to both the cell and damage
type, which would explain the slight disparities in the results
reported to date, and provide a mechanism for a context-based
cellular survival versus death decision to bemade.Nevertheless,
the identification and characterization of the kinases involved
in the phosphorylation of p53 are essential to the further eluci-
dation of the regulation of p53.
In addition to the well established activation of p53 by ioniz-
ing andnonionizing radiation, anoxia, hypoxia, and type I inter-
ferons, more recent research has shown that DNA and RNA
viruses can activate the p53 response (12, 13). It has been pre-
viously shown that human herpesvirus 6B (HHV-6B) infection
of HCT116 and MOLT-3 cancer cell lines induced p53 phos-
phorylation (at Ser15, Ser20, Ser33, and Ser392) and p53 accumu-
lation in both nuclear and cytoplasmic fractions (14, 15). It has
also been shown that HHV-6B-infected cells were mostly non-
apoptotic, and it has been suggested that in this context, p53
phosphorylation and accumulation may act as a survival factor
rather than cell death inducer. Thus, p53 is a central sensor of
both DNA damage and immune system perturbation. The
DNA virus-induced stress provides a novel model to examine
the kinases that target the Ser20 site of p53.
The aim of this studywas to identify the p53 Ser20 kinase that
is activated after HHV-6B infection of MOLT-3 cells and to
investigate whether the Ser20 kinase operates in a dual site
docking-dependent manner, like members of the calcium cal-
modulin kinase superfamily.We show that the enzyme respon-
sible for this virus-induced phosphorylation of p53 is the DNA
damage-regulatory enzyme CK1. These data suggest a domi-
nant role for CK1 in p53 activation after HHV-6B virus infec-
tion and highlight a specific kinase pathway for further integra-
tion into the antiviral sensing machinery of the cell.
EXPERIMENTAL PROCEDURES
Chemicals, Reagents, Recombinant Proteins, and Antibodies—
All reagents were purchased from Sigma unless otherwise
stated. The CK1 inhibitor D4476 was purchased from Merck.
Overlapping synthetic 15-mer biotinylated peptides from the
coding sequence of human p53 (see Table 1) (Mimotopes,Mel-
bourne, Australia) were resuspended in DMSO to a concentra-
tion of 10 mM. Full-length p53 (FLp53)4 tetramers, recombi-
nant DAPK-1 core domain, and recombinant GST-CK1
kinase domain were purified as described previously (3, 11, 18).
DO-1 and DO-12 antibodies to p53 were kindly provided by B.
Vojtesek (Masaryk Memorial Cancer Institute, Brno, Czech
Republic). Antibodies to p53 phosphorylated at Thr18 (P-p53
Thr18) and Ser392 (P-p53 Ser392) were described previously (16).
1F6 and VC1 antibodies to VRK1 were generated as described
previously (17). P-p53 Ser15 antibody to p53 phosphorylated at
Ser15 and an antibody against CK1 were purchased from Cell
Signaling Technology (supplied by New England Biolabs,
Hitchin, UK). P-p53 Ser20 antibody to p53 phosphorylated at
Ser20 and antibodies against CK1, CHK1, and CHK2 were
obtained fromSantaCruz Biotechnology, Inc. (SantaCruz, CA)
(supplied by Insight Biotechnology,Wembley, UK). Antibodies
to AMPK1, AMPK2, and CK2 were purchased fromUpstate
(Millipore,Watford, UK); an antibody to DAPK-1 was fromBD
Biosciences (Oxford, UK); and antibodies to DAPK-2 and
DAPK-3 were from Abcam (Cambridge, UK). Rabbit anti-
mouse or swine anti-rabbit secondary antibodies were obtained
fromDako (Ely, UK), and donkey anti-goat secondary antibody
was purchased from Santa Cruz Biotechnology.
Purification of the p53 Ser20 Kinase—ThehumanT-cell acute
lymphoblastic leukemia cell line, MOLT-3, was infected with
HHV-6B strain PL-1 as previously described (14). High salt
extracts were prepared from MOLT-3 cells infected with or
without HHV-6B for 48 h. Briefly, cells were lysed in 20 mM
Tris-HCl (pH 7.5), 0.5 M NaCl, 1 mM Na2EDTA, 1 mM EGTA,
1% (v/v) Triton X-100, 2.5 mM Na4P2O7, 1 mM -glycerophos-
phate, 1 mM Na3VO4, and 1 g/ml leupeptin. Lysates were
treated with Benzonase nuclease (Merck), syringed, and col-
lected after centrifugation at 12,000 rpm for 5min at 4 °C. Frac-
tionation of kinase activity fromhigh salt lysates was performed
using a Q-Sepharose Fast Flow anion exchanger with a linear
gradient of 0–1 M KCl in a 10-column volume of 20mMHEPES
(pH 8.0), 10% (v/v) glycerol, 1 mM dithiothreitol (DTT), 1 mM
benzamidine, and protease inhibitor mixture tablets (Roche
Applied Science). The flow-through and 42 12-ml fractions
were collected and assayed for their in vitro kinase activity
toward FLp53 tetramers (see below), and positive fractions
were pooled. Further fractionation of kinase activity from the
positive fractions was performed using a Reactive Brown
10-agarose cation exchanger with a linear gradient of 10 mM to
2 M KCl in a 20-column volume of 25 mMHEPES (pH 7.5), 10%
(v/v) glycerol, 0.02% (v/v) Triton X-100, 1 mMDTT, 1 mM ben-
zamidine, and protease inhibitormixture tablets. Flow-through
and 77 1.3-ml fractions were collected and assayed as above,
and positive fractions were pooled. A final fractionation of
kinase activity was performed using aHiTrap SP-SepharoseHP
cation exchanger (GE Healthcare) with a linear gradient of 10
mM to 2 M KCl in a 20-column volume of 25 mM HEPES (pH
7.5), 10% (v/v) glycerol, 0.02% (v/v) Triton X-100, 1 mMDTT, 1
mM benzamidine, and protease inhibitor mixture tablets. The
flow-through and 100 1-ml fractions were collected and
assayed as above.
InVitroKinaseAssays—FLp53 tetramer in vitro kinase assays
were described previously (18). Briefly, the kinase source (0.2–2
l of lysate or fraction or flow-through, 0.2 l of DAPK-1 core
domain, or 1l of recombinantGST-CK1) was incubatedwith
p53 substrate (100 ng of FLp53 tetramers) in a 20-l reaction
volume containing 25 mM HEPES (pH 7.5), 25 mM KCl, 1 mM
MgCl2, 20 M EDTA, 0.1 mM DTT, and 0.1 mM ATP. Reaction
mixtureswere incubated at 30 °C for 45min, and reactionswere
4 The abbreviationsusedare: FLp53, full-lengthp53;GST, glutathione S-trans-
ferase; P-p53, phosphorylated p53; DTT, dithiothreitol; bis-tris, 2-[bis(2-hy-
droxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; MS, mass spec-
trometry; MS/MS, tandemmass spectrometry.
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terminated by the addition of 30 l of SDS sample buffer con-
taining 0.2 M DTT. Peptide kinase assays were performed by
incubating p53 peptide fragments with the above described
kinase reaction mixtures for 20 min at room temperature prior
to the addition of the kinase source. p53 peptides fragments
were added to a final concentration of 200M.Negative control
reactions, lacking either the kinase source or the kinase sub-
strate were included, along with DMSO solvent controls for
peptide kinase assays.
CK1 Inhibitor Experiments—Mock-infected and HHV-6B-
infected MOLT-3 cells were treated with 10–100 M CK1
inhibitor D4476, concomitantly with infection, for 48 h. Alter-
natively, MOLT-3 cells were pretreated with 10–60 MD4476
for 44 h before exposure (or sham exposure) to a 6-gray x-ray
and further culture for 4 h. DMSO solvent controls were
included, and cells were lysed as described previously (15).
Western Blotting—Lysates, flow-through, fractions, eluates,
or kinase assay samples (10 l) were resolved by SDS-PAGE
through 10% (w/v) Tris-glycine gels and transferred onto nitro-
cellulose membranes (Hybond ECL; GE Healthcare). Mem-
branes were probed with primary antibodies, followed by sec-
ondary antibodies conjugated to horseradish peroxidase.
Bound antibody was detected by ECL.
Mass Spectrometry—Fractions from the HiTrap SP-Sepha-
rose HP cation exchanger column (1 ml each) were concen-
trated 25-fold using Centricon YM10 centrifugal devices
(Millipore). Flow-through and fractions (10 l) were resolved
by SDS-PAGE through a 4–12% (w/v) bis-tris gel (Invitrogen)
and stained with colloidal blue (Invitrogen). Proteins enriched
in the peak fraction (fraction 31) were excised from the gel,
protein in-gel digestions were performed with 0.1 pmol/l
trypsin gold (Promega, Southampton, UK), and extracted
peptides were resuspended in 2% (v/v) formic acid. Samples
were analyzed by tandem mass spectrometry (MS/MS).
Briefly, peptides were resolved in a gradient of 4–95% (v/v)
MeCN using reverse phase high performance liquid chroma-
tography, using the UltiMate 3000 system (Dionex, Camber-
ley, UK). Samples were acquired on a 4000 Q TRAP liquid
chromatography/MS/MS system (Applied Biosystems,War-
rington, UK). Data were analyzed using Analyst software
(Applied Biosystems).
Immunoprecipitation—Peak fractions from the HiTrap SP-
Sepharose HP cation exchanger column (25l) were incubated
with primary antibody (0.25–2 l VC1 antibody to VRK1 or
antibody to CK1) overnight at 4 °C in immunoprecipitation
buffer (0.1% (w/v) SDS, 1% (v/v) Nonidet P-40, 50mMTris-HCl
(pH 7.4), 150 mMNaCl, 1 mM EDTA) in a final volume of 50 l.
Protein G-Sepharose Fast Flow beads (50 l) were then added,
and the reactions were incubated at 4 °C for a further 2 h. The
flow-throughwas collected and assayed for in vitro kinase activ-
ity toward FLp53 tetramers, and the beads were washed six
times in 100 l of immunoprecipitation buffer. Bound protein
was eluted after a 45-min incubation in 100 l of elution buffer
(SDS sample buffer containing 0.2 M DTT) at room tempera-
ture. Negative control reactions, where the antibody was omit-
ted, were included.
RESULTS
HHV-6B-infected MOLT-3 Cells Contain a Kinase That
Displays Ser20 Site Activity toward p53 in Vitro—HHV-6B
infection has previously been shown to induce Ser20 site
phosphorylation of p53, although the kinase that mediates
this stress-activated phosphorylation has not been identified
(14). We set out to determine whether HHV-6B-infected
MOLT-3 cell lysates were capable of mediating the phospho-
rylation of p53 at Ser20 in an in vitro assay. HHV-6B-infected
MOLT-3 whole-cell lysates acted as the kinase source in an
in vitro kinase assay using recombinant FLp53 tetramers as
the substrate. Western blotting of the kinase assay products
revealed that p53 was phosphorylated at Ser20 (Fig. 1, lanes
1–4) and that the amount of P-p53 Ser20 was proportional to
the amount of kinase source used in the kinase assay. HHV-
6B-infected MOLT-3 cell lysates therefore contain at least
one kinase that is capable of mediating the phosphorylation
of p53 at Ser20 in vitro.
In order to identify the p53 Ser20 kinase, we subjected
crude lysates to chromatographic fractionation to determine
whether the kinase activity correlates with the known Ser20
site kinases, including CHK1/2 and DAPK-1. HHV-6B-in-
fected and mock-infected MOLT-3 whole-cell lysates were
applied onto a Q-Sepharose Fast Flow anion exchanger col-
umn, proteins were eluted in a linear gradient of 0–1 M KCl,
and fractions were collected and assayed for kinase activity
toward the Ser20 and Ser15 sites of FLp53 (Fig. 2). The induc-
tion of Ser20 site phosphorylation correlated with an increase
in the specific activity of the Ser20 site kinase. The kinase
eluted from fractions 14–18 in mock-infected cells (Fig. 2A,
upper panels, lanes 9–11), whereas in HHV-6B-infected
cells, the kinase eluted from fractions 10–20 (Fig. 2A, lower
panels, lanes 7–12) and a broader elution peak from frac-
tions 26–48 (lanes 15–26). By contrast, the induction of
Ser15 site phosphorylation after HHV-6B infection did not
exhibit the same qualitative increase in cell-free kinase activ-
ity (Fig. 2B). When these fractions containing the peak Ser20
site kinase activity were immunoblotted for the kinases
known to phosphorylate p53 Ser20, none of the calcium cal-
modulin kinase superfamily members co-eluted precisely
with the Ser20 site kinase activity (data not shown). Thus, we
FIGURE 1. HHV-6B-infected MOLT-3 lysates display cell-free p53 Ser20
kinaseactivity.MOLT-3 cellswere infectedwithHHV-6B for 48hprior to lysis.
Decreasing amounts of the whole-cell lysates (10-fold serial dilutions in lanes
1–5) acted as the kinase source in an in vitro kinase assay using recombinant
FLp53 tetramers as the substrate. Kinase assay samples were subjected to
Western blotting using P-p53 Ser20 (top) and DO-12 (bottom) antibodies to
detect FLp53 phosphorylated at Ser20 and total FLp53, respectively.
CK1-mediated Phosphorylation of p53 at Serine 20
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set up further chromatographic
fractionations in order to enrich
the HHV-6B-induced Ser20 site
kinase activity sufficiently to iden-
tify candidate leads by identifying
protein bands from SDS-PAGE
gels using mass spectrometry
(MS).
Purification of the p53 Ser20
Kinase—Large scaled up samples of
HHV-6B-infected MOLT-3 whole-
cell lysates were applied onto a
Q-Sepharose Fast Flow anion
exchanger column, proteins were
eluted in a linear gradient of 0–1 M
KCl, and fractions were collected
and assayed for kinase activity
toward the Ser20 site of FLp53 (Fig.
3A). Fractions 9–14 containing the
most activity (Fig. 3A, lanes 5–8)
were pooled and applied onto a
Reactive Brown 10-agarose cation
exchange column. Proteins were
eluted in a linear gradient of 10 mM
to 2 M KCl, and fractions were col-
lected and assayed for kinase activ-
ity toward FLp53 Ser20, as described
previously (Fig. 3B). Fractions
17–23 containing the first peak of
activity (Fig. 3B, lanes 11–14) were
pooled and applied onto a HiTrap
SP-Sepharose HP cation exchanger
column. Proteins were eluted in a
linear gradient of 10 mM to 2 M KCl,
and fractions were again collected
and assayed for kinase activity
toward FLp53 Ser20 (Fig. 3C). Frac-
tion 29 displayed the most activity
toward FLp53 Ser20 (Fig. 3C,
lane 11).
The p53 Ser20 Kinase Is CK1—
None of the calcium calmodulin
kinase superfamily members
co-eluted with the fractions from
theHiTrap SP-SepharoseHP cation
exchanger column that displayed
the peak of p53 Ser20 kinase activity
(Fig. 4, lane 10). As such, we
resolved protein from the peak frac-
tions by SDS-PAGE, and after stain-
ing with colloidal blue (Fig. 5A, left),
we excised and processed the pro-
teins that were enriched in the peak
fraction (Fig. 5A, right, lane 5 versus
lane 4 or 6) for analysis by MS in
order to acquire candidate kinase
leads. MS identified VRK1 (47 kDa)
and CK1 (38 kDa) as candidate
FIGURE 2. p53 Ser20 kinase activity is elevated in HHV-6B-infected MOLT-3 cell lysates. Mock-infected
(top) and HHV-6B-infected (bottom) MOLT-3 whole-cell lysates were subjected to chromatographic fraction-
ation using a Q-Sepharose Fast Flow anion exchanger with a linear gradient of 0–1 M KCl. Even-numbered
fractions (lanes 3–27) were assayed for in vitro kinase activity toward recombinant FLp53 tetramers, andWest-
ern blotting using P-p53 Ser20 and P-p53 Ser15 antibodies revealed phosphorylation at the Ser20 (A) and Ser15
(B) sites of FLp53. Input (I; lane 1) and negative (; lane 2) controls were included and consisted of unfraction-
ated whole-cell lysates and distilled H2O as the kinase source, respectively.
FIGURE 3. Purification of the virus-induced p53 Ser20 kinase. A, HHV-6B-infected MOLT-3 whole-cell
lysates were subjected to chromatographic fractionation using a Q-Sepharose Fast Flow anion exchanger
with a linear gradient of 0–1 M KCl. The column flow-through (FT; lane 2) and odd-numbered fractions
(lanes 3–18) were assayed for in vitro kinase activity toward the Ser20 site of FLp53 tetramers, which was
detected by Western blotting using P-p53 Ser20 (top) and DO-12 (bottom) antibodies. A negative control
(; lane 1), consisting of distilled H2O as the kinase source, was included. B, fractions 9–14 from A were
pooled and subjected to further chromatographic fractionation using a Reactive Brown 10-agarose cation
exchanger with a linear gradient of 0.01–2 M KCl. The column flow-through (lane 2) and odd-numbered
fractions (lanes 3–24) were assayed for in vitro kinase activity toward the Ser20 site of FLp53 tetramers,
which was detected by Western blotting using P-p53 Ser20 (top) and DO-12 (bottom) antibodies. A nega-
tive control (; lane 1), consisting of distilled H2O as the kinase source, was included. C, fractions 17–23
from B were pooled and subjected to a final chromatographic fractionation using a HiTrap SP-Sepharose
HP cation exchanger with a linear gradient of 0.01–2 M KCl. The column flow-through (lane 3) and every
fourth fraction (lanes 4–27) were assayed for in vitro kinase activity toward the Ser20 site of FLp53 tetram-
ers, which was detected by Western blotting using P-p53 Ser20 (top) and DO-12 (bottom) antibodies.
Negative (; lane 1) and input (I; lane 2) controls were included and consisted of distilled H2O and pooled
fractions 17–23 from B as the kinase source, respectively.
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kinases that eluted in fraction 31 (Fig. 5,B andC), a fraction that
displayed strong kinase activity toward the Ser20 site of FLp53.
Western blotting confirmed that the elution profiles of CK1
or CK1 (Fig. 6, A and B) and VRK1 (Fig. 6C) matched the p53
Ser20 kinase activity profile. CK1 and CK1 eluted mostly in
fraction 29 (Fig. 6, A and B, lanes 10 and 9, respectively), and
VRK1 eluted in fractions 29–33 (Fig. 6C, lanes 10 and 11), sug-
gesting that either kinase could be responsible for the observed
phosphorylation of FLp53 at Ser20 in the peak fraction 29 (Fig.
3C). Immunoprecipitation studies revealed that the kinase
activity toward FLp53 at Ser20 was attenuated after immu-
nodepletion of CK1 (Fig. 7A, lanes 4–7 versus lane 3) and not
after depletion of VRK1 (Fig. 7A, lanes 9–12 versus lane 8),
implying that CK1 is the dominant p53 Ser20 kinase. This
agrees with previous data showing that recombinant VRK1
does not exhibit Ser20 site kinase activity (10). However, this
does rule out VRK1 as a co-purifying subunit of CK1. As con-
trols, we affirmed that increasing the antibody titration did
result in reduced CK1 (Fig. 7B, lanes 2–5 versus lane 1) and
VRK1 (Fig. 7C, lanes 2–5 versus lane 1) in the immunodepleted
samples as well as elevated CK1 (Fig. 7B, lanes 7–10 versus
lane 6) and VRK1 (Fig. 7C, lanes 7–10 versus lane 6) in the
immune pellet.
Together, these results demonstrate that CK1 is the most
likely cellular virus-induced Ser20 site kinase. However, we still
set up assays to compare recombinant CK1 kinase domain
purified from Escherichia coli with the native enzyme purified
from MOLT-3 cells in order to determine whether the native
enzyme has the same properties as the recombinant CK1.
Recombinant CK1 was able to mimic the native enzyme and
catalyze Ser20 site phosphorylation of FLp53 tetramers in vitro
(Fig. 8A, lane 5 versus lane 3). This finding is consistent with the
original data on CK1, which showed that mutation of p53 at
Ser20 is sufficient to block com-
pletely p53 phosphorylation (11).
We could not detect p53 Thr18
phosphorylation induced by native
or recombinant CK1 using a well
validated Thr18-phosphospecific
monoclonal antibody (Fig. 8B, lanes
3 and 5), which might be expected,
since recombinant CK1-mediated
phosphorylation at Thr18 requires a
prior phosphorylation of p53 at
Ser15 by phosphoinositide 3-kinases
(11).
The Phosphorylation of p53 at
Ser20 by Native CK1 Is Dependent
on Interactions with the BOX-IV
and BOX-V Domains of p53—All
enzymes reported to modify the
Thr18 or Ser20 sites within the
BOX-I domain of p53 to date also
interact with themultiprotein dock-
ing site in the BOX-V domain of p53
(Fig. 9). The three-dimensional
proximity of theBOX-Vmotif to the
BOX-Imotif in tetrameric p53 is not
known. However, synthetic peptide
fragments from the BOX-V domain
of p53 can alter in trans the BOX-I
Ser20 site kinase activity of the
FIGURE 4.Calciumcalmodulin kinasesdonot co-elutewith virus-induced
p53 Ser20 kinase activity. The flow-through (FT; lane 2) and every fourth
fraction (lanes 3–27) from the HiTrap SP-Sepharose HP cation exchanger col-
umn were subjected to Western blotting with antibodies against known cal-
cium calmodulin kinase superfamily members (AMPK1, AMPK2, CHK1,
CHK2, CK2, DAPK-1, DAPK-2, andDAPK-3). An input control (I; lane 1), consist-
ing of pooled fractions 17–23 from the Reactive Brown 10-agarose cation
exchanger column, was included.
FIGURE 5. Mass spectrometry identifies VRK1 and CK1 as candidate p53 Ser20 kinases. A, the flow-
through (FT; lane 2) and concentrated fractions 27, 28, 31, and 32 (lanes 3–6) from the HiTrap SP-Sepharose HP
cation exchanger columnwere resolved by SDS-PAGE and stainedwith colloidal blue (left). An input control (I;
lane 1), consisting of pooled fractions 17–23 from the Reactive Brown 10-agarose cation exchanger column,
was included. Proteins enriched in fraction 31 (lane 5) were excised from the gel (right) and processed for
analysis by MS/MS. B and C, MS identified VRK1 (B) and CK1 (C) as candidate kinases.
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respective enzymes (18, 19). Kinase assays were performed
using peptides designed to the BOX-IV and BOX-V domains of
the coding sequence of human p53 (Fig. 9 and Table 1) in order
to monitor peptide stimulation or inhibition of kinase function
toward FLp53 tetramers (Fig. 10). Several peptides (peptides
2–4, 12 and 13, and 16 and 17) had an inhibitory effect on the
kinase activity ofCK1 toward the Ser20 site of FLp53 tetramers
(Fig. 10A, lanes 5–7, 15 and 16, and 19 and 20). This implies that
residues 251–253, 261–262, and 265–266 of p53 encompass
docking sites in the BOX-IV and BOX-V domains that are cru-
cial for the Ser20 site activity of CK1. The location of these key
docking sites within the localized three-dimensional structure
of p53 is shown in Fig. 10C.
Distinct Residues in the BOX-IV and BOX-V Domains of
p53 Are Important for the Interaction of p53 with Different
Proteins—We evaluated whether DAPK-1 core domain has a
similar or overlapping sensitivity to the p53 BOX-IV and
BOX-V peptides as native CK1. Several peptides (peptides 4
and 5, 13–16, and 18) had an inhibitory effect on the kinase
activity of DAPK-1 core toward the Ser20 site of FLp53 tet-
ramers (Fig. 10B, lanes 7 and 8, 16–19, and 21). This implies
that residues 253–254, 262–265, and 267 in the BOX-IV and
BOX-V domains of p53 are important for the Ser20 site activ-
ity of DAPK-1 core. The location of these key docking sites
within the three-dimensional structure of p53 is shown in
Fig. 10D. These data indicate that at least two distinct
kinases have an overlapping, but nonidentical, interaction
with the BOX-IV and BOX-V domains of p53.
CK1 Inhibitors Attenuate p53 Induction by HHV-6B
Infection—In order to obtain independent genetic evidence
that CK1 is the major Ser20 site kinase for p53 in HHV-6B-
infected cells, we needed to inhibit the enzyme to determine
whether p53 induction would be reduced. TheMOLT-3 cells
are well known to be difficult to transfect using small inter-
fering RNA, so we could not
deplete endogenous CK1 using
this approach. However, there are
three chemical inhibitors of CK1
that can be used, one of which
(D4476) shows a more pro-
nounced specificity for CK1 (31).
Upon increasing addition of
D4476 to HHV-6B-infected
MOLT-3 cells, there was a dose-
dependent reduction in Ser20 site
phosphorylation (Fig. 11A, top,
lanes 4–14 versus lane 2). This
reduction was especially pro-
nounced from a concentration of
20 M D4476 and higher (Fig. 11A,
top, lanes 6–14 versus lane 2). This
inhibition of p53 Ser20 site phos-
phorylation did not result in loss
of CK1 enzyme (Fig. 11A, third
panel, lanes 4–14 versus lane 2);
however, there was an increase in a
higher molecular weight adduct at
the 20 M concentration of D4476
irrespective of HHV-6B infection status (Fig. 11A, third
panel, lanes 5 and 6 versus lanes 1 and 2).
Although previous studies were unable to show a reduction
in HHV-6B-induced phosphorylation of p53 at Ser15, Ser20, or
Ser392 using chemical inhibitors designed to CK2, double-
stranded RNA-activated protein kinase, or p38 mitogen-acti-
vated protein kinase (15), we evaluated whether CK1 inhibition
of Ser20 site phosphorylation could be uncoupled from HHV-
6B-induced phosphorylation at other sites. At the concentra-
tions of D4766 where we began to observe reductions in Ser20
site phosphorylation (10 and 20 M), there was no reduction
detected in HHV-6B induction of Ser15 or Ser392 phosphoryla-
tion of p53 (Fig. 11, B and C, top, lanes 4 and 6 versus lane 2).
However, from a concentration of 40 M D4476 and higher,
there was a complete inhibition of HHV-6B-induced Ser15 site
phosphorylation (Fig. 11B, top, lanes 8–14) but not Ser392 site
phosphorylation (Fig. 11C, top, lane 8). Only at concentrations
of 60 M D4476 or higher did we see inhibition of Ser392 site
phosphorylation of p53 (Fig. 11C, top, lanes 10–14 versus lane
2). Together, these data suggest that CK1 may not only be the
Ser20 site kinase after virus infection but that there might be a
degree of cross-talk between CK1 and the enzymes that medi-
ate p53 phosphorylation at Ser15 and Ser392.
CK1 Inhibitors Do Not Attenuate p53 Induction by X-ray
Treatment—We next set out to determine whether CK1 is a
global Ser20 site kinase for p53 in response to a wide range of
stresses or whether CK1 acts specifically in response to viral
infection. MOLT-3 cells were therefore treated with and with-
out a 6-gray x-ray in the presence of increasing amounts of the
CK1 inhibitor D4476. Although x-rays induced the phospho-
rylation of p53 at Ser20 along with an increase in p53 levels (Fig.
12, even-numbered lanes versus odd-numbered lanes), increas-
ing the addition of D4476 did not attenuate either the Ser20 site
phosphorylation or the induction of p53 (Fig. 12, lanes 6–12
FIGURE 6.CK1, CK1, andVRK1 co-elutewithp53Ser20 kinase activity. The flow-through (FT; lanes 1 and 2)
and every fourth fraction (lanes 2–26or 3–27) from theHiTrap SP-SepharoseHP cation exchanger columnwere
subjected toWestern blottingwith antibodies against CK1 (A), CK1 (B), or VRK1 (C). An input control (I; lane 1),
consisting of pooled fractions 17–23 from the Reactive Brown 10-agarose cation exchanger column, was
included in A and C.
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versus lanes 2 and 4). The data therefore suggest that CK1 is a
virus-specific Ser20 site kinase for p53 and that other kinases are
responsible for mediating the phosphorylation of p53 at Ser20
after distinct stresses, such as x-rays.
DISCUSSION
The p53 tetramer is subject to a complex set of diverse post-
translational modifications that are induced in a coordinated
manner by stress-activated pathways. These covalent adducts
include phosphorylation, ubiquitination, acetylation, addi-
tional ubiquitin-like modifications, and methylation. These
modifications occur within different domains of the p53 pro-
tein and result in distinct effects both on the tetrameric confor-
mation and the protein interaction network of p53, and they
ultimately affect the specific activity of p53. These post-trans-
lational modifications are catalyzed by a range of enzymes,
including p300, UBCH5/Mdm2, cyclin-dependent kinases,
CK2, and CHK2. A feature of these enzymatic modifications is
that they occur through enzyme docking tomultiple linear pep-
tide interaction sites within the p53 tetramer (2). Presumably,
p53 has therefore evolved these unstructured and flexible
motifs common to regulatory enzymes in order to coordinate
multiple stress-activated signaling events.
Since phosphorylation of the Ser20 site of p53 plays a domi-
nant role in stabilizing p300 and mediating DNA-dependent
acetylation of p53, as well as B-cell lymphoma suppression, it is
of interest to define the environmental stresses and the kinases
that mediate this phosphorylation. Studies originally high-
lighted that CHK1 and CHK2 were the major Ser20 kinases for
p53, although this has been questioned (20, 21). Subsequent
work has shown that members of the calcium calmodulin
kinase superfamily, including CHK1, CHK2, AMPK (AMP-ac-
tivated protein kinase), DAPK-1, DAPK-3, and DRAK-1
(DAPK-related 1) can phosphorylate the Thr18 and/or Ser20
residues of p53 in a cell-free assay (18). These kinases, including
CHK1/2, modify p53 in a dual site docking-dependent manner.
This shows that phosphorylation events within the BOX-I
domain of p53 are dependent on kinase docking interactions
FIGURE 7. Immunodepletion of CK1, but not VRK1, abolishes p53 Ser20
kinase activity. CK1 or VRK1 were immunoprecipitated from a peak frac-
tion from the HiTrap SP-Sepharose HP cation exchanger column using
increasing amounts (0.25–2l) of antibody toCK1or VRK1bound to Protein
G-Sepharose Fast Flow beads. A, immunodepleted fractions, or flow-through
(FT; lanes 3–12),were assayed for in vitro kinaseactivity toward theSer20 siteof
FLp53 tetramers, which was detected by Western blotting using P-p53 Ser20
(top) and DO-12 (bottom) antibodies. Negative (; lane 1) and input (I; lane 2)
controlswere included and consisted of distilledH2Oand thepeak fraction as
the kinase source, respectively. Fractions depleted of CK1 and VRK1 are
shown in lanes 4–7 and lanes 9–12, respectively, and negative control reac-
tions, where the antibody was omitted, are shown in lanes 3 and 8. B and C,
immunodepleted fractions, or flow-through (lanes 1–5), and the correspond-
ing immunepellet, or eluate (lanes 6–10), were subjected toWestern blotting
with antibodies to CK1 (B) or VRK1 (C). Fractions depleted of CK1 and VRK1
are shown in B and C, respectively, and negative control reactions, where the
antibodywas omitted from the immunoprecipitation reactions, are shown in
lanes 1 and 6.
FIGURE 8. Native and recombinant CK1 phosphorylate p53 at Ser20.
Native CK1 purified from HHV-6B-infected MOLT-3 cells (lanes 2 and 3) or
recombinant GST-CK1 kinase domain purified from E. coli (lanes 4 and 5) was
assayed for in vitro kinase activity toward the Ser20 (A) and Thr18 (B) sites of
FLp53 tetramers, which was detected by Western blotting using P-p53 Ser20
(A, top), P-p53 Thr18 (B, top), andDO-12 (A and B, bottom) antibodies. Negative
control reactions, lacking either the kinase source (lane 1) or the kinase sub-
strate (lanes 2 and 4) were included.
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within the conformationally flexible BOX-V domain of p53
(model depicted in Fig. 13A). Similarly, recent work has also
shown that the ubiquitination of p53 by Mdm2 is regulated
by a related dual site mechanism. Stimulation of the ubiq-
uitin ligase function of Mdm2 requires the interaction of
Mdm2 both with the BOX-I domain of p53 and with a ubiq-
uitination signal found within the BOX-V domain of p53
(22). It is therefore becoming increasingly apparent that the
BOX-V domain of p53 is a key multiprotein docking region,
equivalent to the BOX-I domain, with both activating kinases
and negative regulators potentially competing for binding to
overlapping motifs (Fig. 13A).
Although DNA damage induced by radiation has been the
most well characterized stress that activates p53, perhaps more
biologically intrinsic stresses have also been reported that have
not been as well dissected. These include hypoxia, interferon-
signaling, and DNA or RNA virus infection. A range of DNA or
RNA viruses can induce p53-dependent apoptosis in some cell
types (23, 24). Further, type I inter-
ferons can activate p53-dependent
processes in animal models (12).
Whether these interferon signaling
effects occur in dendritic cells
and/or macrophages and how this
alters immune system integrity in
either normal or cancer cells
remains to be determined. The link
between p53 and interferon or virus
responses is particularly intriguing,
since a role for p53 in immunity
might have been the physiological
selection pressure under which the
p53 pathway appeared during evo-
lution in chordates. Thiswould have
occurred evolutionarily to maintain
host survival during viral or patho-
gen infection. Indeed, some tumor
viruses have evolved proteins that
bind to and inactivate or degrade
p53, thus permitting virus propagation. Understanding the
kinase signaling pathways that cells use to activate p53 after
virus infection should provide fundamental insights into the
physiology of the p53 response to immune system stresses.
Although there is a range of RNA and DNA viruses that have
been reported to activate p53-dependent processes, we have
used HHV-6B as a model. This virus is thought to be the most
ancient, foundingmember of theHHV family of viruses and has
the unusual property of inducing growth arrest rather than apo-
ptosis in infected T-cells (14, 25).
HHV-6Bhas previously been reported to induce phosphoryl-
ation of p53 at Ser15, Ser20, Ser33, and Ser392 (14, 15). Phospho-
rylation at Thr18 after viral infection cannot be detected in this
system (data not shown). Of these sites, the Ser20 and Ser392
phosphoacceptor site mutations have been made in animal
transgenic models and result in stress-induced or cell-specific
tumor-prone phenotypes (7–9). The Ser20 phosphoacceptor
site has appeared rather late in evolution, since it is found only
in mammals. The phosphorylation of p53 at Ser20 has the most
striking effect in stabilizing the binding of p300 (4), which in
turn stimulates the DNA-dependent acetylation of p53 (3, 26).
Interestingly, although the Ser20 site is confined to mammals,
certain fish species have evolved a negatively charged amino
acid at this position, suggesting that other vertebrates also
exploit this site to anchor p300. Defining which kinase path-
way(s) targets the Ser20 site after viral infection will help us to
identify potential evolutionarily core signaling pathways that
have maintained mammalian host survival under the natural
selection imposed by virus infection.
In this report, we identify CK1 as the dominant enzyme that
catalyzes Ser20 site phosphorylation of p53 after viral infection.
This conclusion is based on (i) the purification of the virus-
induced Ser20 site kinase away from the known Ser20 site
kinases, includingCHK1/2 andDAPK-1, (ii) the immunodeple-
tion of p53 Ser20 kinase activity from infected cell lysates, and
(iii) the ability of a relatively specific CK1 inhibitor to attenuate
virus-induced Ser20 site phosphorylation in cells. Like all
FIGURE 9. Location of the synthetic peptides within the coding sequence of p53. The domain structure of
p53 (393aminoacids) is represented, including the conserveddomains, labeledwith the indicatedaminoacids
flanking BOX-I through BOX-V. Overlapping synthetic 15-mer peptideswere designed to the BOX-IV and BOX-V
domains of the coding sequence of human p53. See Table 1 for peptide sequences.
TABLE 1
p53 peptide amino acid sequences
Shown are overlapping synthetic 15-mer peptides from the coding sequence of
humanp53.All peptideswere biotinylated at theN terminuswith SGSG spacers and
had a C terminal amide group.
Peptide Sequence
Peptide 1 NRRPILTIITLEDSS
Peptide 2 ILTIITLEDSSGNLL
Peptide 3 LTIITLEDSSGNLLG
Peptide 4 TIITLEDSSGNLLGR
Peptide 5 IITLEDSSGNLLGRN
Peptide 6 ITLEDSSGNLLGRNS
Peptide 7 TLEDSSGNLLGRNSF
Peptide 8 LEDSSGNLLGRNSFE
Peptide 9 EDSSGNLLGRNSFEV
Peptide 10 DSSGNLLGRNSFEVR
Peptide 11 SSGNLLGRNSFEVRV
Peptide 12 SGNLLGRNSFEVRVC
Peptide 13 GNLLGRNSFEVRVCA
Peptide 14 NLLGRNSFEVRVCAC
Peptide 15 LLGRNSFEVRVCACP
Peptide 16 LGRNSFEVRVCACPG
Peptide 17 GRNSFEVRVCACPGR
Peptide 18 RNSFEVRVCACPGRD
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enzymes reported to modify the Thr18 or Ser20 sites of p53 to
date, CK1 also interacts with the multiprotein docking site in
the BOX-V domain of p53 (model illustrated in Fig. 13A). Fur-
ther, despite the fact that CK1 can catalyze p53 phosphoryla-
tion at Thr18 (27), with a prior DNA damage-inducible modifi-
cation at Ser15 by phosphoinositide 3-kinases, the original
characterization of CK1 specificity in targeting the transacti-
vation domain of p53 showed that mutation of the Ser20 site
resulted in the most pronounced block of p53 phosphorylation
(11).
The function of CK1 in virus signalingwas only recently real-
ized, in part, due to the availability of relatively specific inhibi-
tors of CK1. In particular, CK1 was implicated in mediating
FIGURE12.ACK1 inhibitordoesnot attenuateSer20 sitephosphorylation
of p53 and p53 induction mediated by treatment with x-rays. MOLT-3
cells were treated with (even-numbered lanes) or without (odd-numbered
lanes) 6-gray x-ray and cultured for 4 h after an initial 44-h pretreatment with
increasing concentrations (10–60 M) of the CK1 inhibitor D4476 (lanes
5–12), a DMSO solvent control (lanes 3 and 4), or a culture medium control
(lanes 1 and 2). Cell lysates were examined byWestern blottingwith antibod-
ies against the indicated proteins.
FIGURE 10. The BOX-IV and BOX-V domains of p53 act as multiprotein
docking sites necessary for the p53 Ser20 kinase activity of CK1 and
DAPK-1.A andB, nativeCK1purified fromHHV-6B-infectedMOLT-3 cells (A)
or DAPK-1 core domain (B) were assayed for in vitro kinase activity toward the
Ser20 site of FLp53 tetramers in the presence of p53 BOX-IV and BOX-V pep-
tides (lanes 4–21) or a DMSO solvent control (lane 3). Western blotting using
P-p53 Ser20 (top) andDO-12 (bottom) antibodies revealed FLp53 phosphoryl-
ated at Ser20 and total FLp53, respectively. Negative control reactions (; lane
1) lacking the kinase source and positive or input controls (I; lane 2) with the
kinase source were included. C and D, location of key CK1 (C) or DAPK-1 (D)
docking sites within the BOX-IV and BOX-V domains of the three-dimensional
structure of p53 that are necessary for the p53 Ser20 kinase activity of either
CK1 (C) or DAPK-1 (D). Highlighted docking regions encompass residues
251–253 (a), 261 and262 (b), 265 and266 (c), 253 and254 (d), 262–265 (e), and
267 (f). The arrows indicate the shift in docking site preferences of DAPK-1
versus CK1. *, the conformationally flexible monoclonal antibody epitope,
which can be exposed or cryptic, depending upon p53 conformation. aa,
amino acids.
FIGURE 11. A CK1 inhibitor attenuates Ser20 site phosphorylation of p53
andp53 inductionmediated byHHV-6B infection. A–C, MOLT-3 cells were
infectedwith (even-numbered lanes) orwithout (odd-numbered lanes) HHV-6B
for 48 h in the presence of increasing concentrations (10–100M) of the CK1
inhibitor D4476 (lanes 3–14) or a DMSO solvent control (lanes 1 and 2). Cell
lysates were examined by Western blotting with antibodies against the indi-
cated proteins.
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NSP5-dependent rotavirus RNA replication (28) and in medi-
ating hepatitis C virusNS5Aprotein hyperphosphorylation (29,
30). Whether cells exploit CK1 to modify p53 after infection by
RNA viruses or other proapoptotic DNA viruses remains to be
established. In addition, whether cells exploit CHK1/2 after
virus infection to target p53 remains to be determined; it may
be a possibility if DNA replication and genome checkpoints
sense and signal to the ataxia telangiectasia-mutated and Rad3-
related (ATM/ATR)-CHK1/2 axis. Further, the function of p53
after HHV-6B infection remains to be determined, and the
changes in gene expression induced by p53 need to be charac-
terized. Presumably the virus-induced Ser20 site phosphoryla-
tion will alter p300 binding and
related p300 co-activated transcrip-
tional targets. However, we do not
know whether this will facilitate
virus survival and replication or
whether it will facilitate host T-cell
responses and organism survival.
Although we identified a novel
role for CK1 in linking the p53
checkpoint pathway to the cellular
response to DNA virus infection,
our studies suggest that distinct
kinases are responsible for mediat-
ing the phosphorylation of p53 at
Ser20 after different stresses (model
depicted in Fig. 13B). For example,
Ser20 site phosphorylation in
response to irradiation damage has
been historically attributed to
CHK1/2. It therefore appears that
distinct stresses lead to the activa-
tion of different p53-activating
kinases, which presumably enables
cells to adopt appropriate stress-
specific responses.
In conclusion, the enzymes that
coordinatelymodify p53 protein after
cell stress form a relatively large fam-
ily of enzymes, including kinases,
acetyltransferase, and ubiquitin con-
jugation enzymes. Although irradia-
tion damage has been the most well
characterized stress-activating sys-
tem for p53, in part because anti-can-
cer agents often function by inducing
DNA damage, more physiological
stresses have not been as well charac-
terized. In particular, the ability of
cells to respond toDNAorRNAvirus
infection by switching on p53 activa-
tion pathways provides an opportu-
nity to identify signaling pathways
that might shed light on how viruses
target the immune system. In this
report, we provide evidence suggest-
ing that CK1 is a major enzyme that
targets the transactivationdomainofp53byphosphorylationafter
HHV-6B infection.OurworkhighlightsCK1asacomponentof an
intriguing pathway that warrants further investigation in order to
understand the interaction between viruses and the mammalian
immune system.
REFERENCES
1. Levine, A. J., Hu,W., and Feng, Z. (2006)Cell Death Differ. 13, 1027–1036
2. Hupp, T. R., and Walkinshaw, M. (2007) Nat. Struct. Mol. Biol. 14,
885–887
3. Dornan, D., Shimizu, H., Perkins, N. D., and Hupp, T. R. (2003) J. Biol.
Chem. 278, 13431–13441
4. Polley, S., Guha, S., Roy, N. S., Kar, S., Sakaguchi, K., Chuman, Y., Swami-
FIGURE 13. Multiprotein docking site and p53 activation models. A, the interaction of CK1 and calcium
calmodulin kinases with the multiprotein docking sites in the BOX-IV and BOX-V domains of p53 allows their
subsequent phosphorylation of Ser20 and/or Thr18 sites within the BOX-I domain of p53. The domain structure
of p53 (393 amino acids) is represented, including the conserved domains, labeled with the indicated amino
acids flanking BOX-I through BOX-V. The BOX-I domain from amino acid 13 to 23 contains the Thr18 and Ser20
phosphorylation sites and the N-terminal docking sites for p300 and MDM2 that are required for acetylation
and ubiquitination of p53, respectively. The BOX-V domain from amino acid 270 to 286 contains the protein
kinase and MDM2 docking sites that are required for phosphorylation and ubiquitination, respectively. B, dif-
ferent kinase signaling pathways link the two distinct stresses of DNA damage and viral infection to p53 Ser20
site phosphorylation and activation. p53 is activated by distinct stresses, including DNA damage, metabolic
stress, oncogene activation, and virus infection. CHK1 and/or CHK2 have been implicated as the most likely
Ser20 site kinases in response to DNA damage (18, 20), but this has been questioned using gene knock-out
technologies (21). Thus, the identity of theDNAdamage-induced Ser20 site kinase is not necessarily evident. By
contrast, this current study demonstrates that DNA virus-induced Ser20 site phosphorylation of p53 is not
mediated by CHK1/2 but rather by CK1. These data support the model that the Ser20 site phosphorylation of
p53 is triggered by distinct stress-responsive signaling cascades, and future analysis will be required to deter-
mine the identity of the enzymes that mediate stress-induced phosphorylation of p53 at this site.
CK1-mediated Phosphorylation of p53 at Serine 20
28572 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 42•OCTOBER 17, 2008
 by guest on August 18, 2013http://www.jbc.org/Downloaded from 
nathan, V., Kundu, T., and Roy, S. (2008) J. Mol. Biol. 376, 8–12
5. Teufel, D. P., Freund, S.M., Bycroft,M., and Fersht, A. R. (2007)Proc. Natl.
Acad. Sci. U. S. A. 104, 7009–7014
6. Hupp, T. R., Sparks, A., and Lane, D. P. (1995) Cell 83, 237–245
7. MacPherson, D., Kim, J., Kim, T., Rhee, B. K., Van Oostrom, C. T., DiTul-
lio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., De Vries, A., Flem-
ing, M., and Jacks, T. (2004) EMBO J. 23, 3689–3699
8. Bruins, W., Zwart, E., Attardi, L. D., Iwakuma, T., Hoogervorst, E. M.,
Beems, R. B., Miranda, B., van Oostrom, C. T., van den Berg, J., van den
Aardweg, G. J., Lozano, G., van Steeg, H., Jacks, T., and de Vries, A. (2004)
Mol. Cell Biol. 24, 8884–8894
9. Bruins, W., Jonker, M. J., Bruning, O., Pennings, J. L., Schaap, M. M.,
Hoogervorst, E. M., van Steeg, H., Breit, T. M., and de Vries, A. (2007)
Carcinogenesis 28, 1814–1823
10. Vega, F. M., Sevilla, A., and Lazo, P. A. (2004) Mol. Cell Biol. 24,
10366–10380
11. Dumaz,N.,Milne, D.M., andMeek,D.W. (1999) FEBS Lett. 463, 312–316
12. Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H.,
Sasaki, S., Imai, K., Shibue, T., Honda, K., and Taniguchi, T. (2003)Nature
424, 516–523
13. Boutell, C., and Everett, R. D. (2004) J. Virol. 78, 8068–8077
14. Oster, B., Bundgaard, B., and Hollsberg, P. (2005) J. Virol. 79, 1961–1965
15. Oster, B., Bundgaard, B., Hupp, T. R., andHollsberg, P. (2008) J. Gen. Virol.
89, 87–96
16. Craig, A. L., Bray, S. E., Finlan, L. E., Kernohan, N. M., and Hupp, T. R.
(2003)Methods Mol. Biol. 234, 171–202
17. Valbuena, A., Lopez-Sanchez, I., Vega, F. M., Sevilla, A., Sanz-Garcia, M.,
Blanco, S., and Lazo, P. A. (2007) Arch. Biochem. Biophys. 465, 219–226
18. Craig, A. L., Chrystal, J. A., Fraser, J. A., Sphyris, N., Lin, Y., Harrison, B. J.,
Scott, M. T., Dornreiter, I., and Hupp, T. R. (2007) Mol. Cell Biol. 27,
3542–3555
19. Craig, A., Scott, M., Burch, L., Smith, G., Ball, K., and Hupp, T. (2003)
EMBO Rep. 4, 787–792
20. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., and Prives, C. (2000) Genes Dev.
14, 289–300
21. Ahn, J., Urist, M., and Prives, C. (2003) J. Biol. Chem. 278, 20480–20489
22. Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R., and Ball, K. L. (2006)
Mol. Cell 23, 251–263
23. Ping-Yuan, L., Hung-Jen, L., Meng-Jiun, L., Feng-Ling, Y., Hsue-Yin, H.,
Jeng-Woei, L., and Wen-Ling, S. (2006) Apoptosis 11, 2179–2193
24. Sun, Y., and Leaman, D. W. (2005) J. Biol. Chem. 280, 15561–15568
25. Pedersen, S. M., and Hollsberg, P. (2006) Virology 356, 1–3
26. Dornan, D., Shimizu, H., Burch, L., Smith, A. J., and Hupp, T. R. (2003)
Mol. Cell Biol. 23, 8846–8861
27. Alsheich-Bartok, O., Haupt, S., Alkalay-Snir, I., Saito, S., Appella, E., and
Haupt, Y. (2008) Oncogene 27, 3653–3661
28. Campagna,M., Budini,M., Arnoldi, F., Desselberger, U., Allende, J. E., and
Burrone, O. R. (2007) J. Gen. Virol. 88, 2800–2810
29. Quintavalle, M., Sambucini, S., Summa, V., Orsatti, L., Talamo, F., De
Francesco, R., and Neddermann, P. (2007) J. Biol. Chem. 282, 5536–5544
30. Quintavalle, M., Sambucini, S., Di Pietro, C., De Francesco, R., and Ned-
dermann, P. (2006) J. Virol. 80, 11305–11312
31. Rena, G, Bain, J., Elliot, M., and Cohen, P. (2004) EMBO Rep. 5, 60–65
CK1-mediated Phosphorylation of p53 at Serine 20
OCTOBER 17, 2008•VOLUME 283•NUMBER 42 JOURNAL OF BIOLOGICAL CHEMISTRY 28573
 by guest on August 18, 2013http://www.jbc.org/Downloaded from 
